IBRX in focus as FDA scrutiny prompts content withdrawal

ImmunityBio (IBRX) stock rose over 3% in pre-market trading after addressing FDA scrutiny regarding its promotional content. The company responded to the FDA's Office of Prescription Drug Promotion, removing a podcast and outlining corrective steps for marketing materials. These actions aim to reinforce compliance standards for its cancer therapy following a March 13 notice.